Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | GHSR | Q92847 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6728514 | 0.83 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CPOLBTAAR1 | |
| SCHEMBL6727683 | 0.82 | KMT2A (0.41) | ADRA2AADRA2BADRA2CPOLBTAAR1 | |
| SCHEMBL6727948 | 0.82 | KMT2A (0.41) | ADRA2AADRA2BADRA2CPOLBTAAR1 | |
| SCHEMBL6728143 | 0.81 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CPOLBTAAR1 | |
| SCHEMBL4111907 | 0.80 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CTAAR1KMT2A | |
| SCHEMBL6728673 | 0.79 | KMT2A (0.40) | ADRA2AADRA2BADRA2CPOLBTAAR1 | |
| SCHEMBL6727571 | 0.79 | ALDH1A1 (0.41) | ADRA2AADRA2BADRA2CPOLBTAAR1 | |
| SCHEMBL6728391 | 0.79 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CPOLBTAAR1 | |
| SCHEMBL6728051 | 0.78 | ALDH1A1 (0.40) | ADRA2AADRA2BADRA2CPOLBTAAR1 | |
| SCHEMBL6727985 | 0.78 | ALDH1A1 (0.43) | ADRA2AADRA2BADRA2CPOLBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370430-B1 | N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-3H-PYRROL-2-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS | ALLERGAN INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8183414-B2 | N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators of ALPHA2B or ALPHA2B and ALPHA2C adrenoceptors | ALLERGAN, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183414-B2 | N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators of ALPHA2B or ALPHA2B and ALPHA2C adrenoceptors | ALLERGAN, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100145061-A1 | N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-2H-PYRROL-5-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS | ALLERGAN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100145061-A1 | N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-2H-PYRROL-5-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS | ALLERGAN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145061-A1 | N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-2H-PYRROL-5-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS | ADRA2B, ADRB2, ADRA2C | ADRA2A 6/4885ADRA2B 1/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.